| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 168 | 2024 | 6987 | 8.720 |
Why?
|
| Multiple Myeloma | 58 | 2024 | 2287 | 4.990 |
Why?
|
| Transplantation, Autologous | 91 | 2024 | 2048 | 4.980 |
Why?
|
| Busulfan | 39 | 2024 | 786 | 3.820 |
Why?
|
| Transplantation Conditioning | 57 | 2023 | 2359 | 3.490 |
Why?
|
| Hodgkin Disease | 28 | 2023 | 1488 | 3.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 90 | 2024 | 16612 | 2.890 |
Why?
|
| Melphalan | 37 | 2023 | 875 | 2.840 |
Why?
|
| Stem Cell Transplantation | 26 | 2023 | 1423 | 2.650 |
Why?
|
| Graft vs Host Disease | 44 | 2024 | 2804 | 2.430 |
Why?
|
| Deoxycytidine | 21 | 2020 | 1378 | 2.320 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 16 | 2023 | 1737 | 2.150 |
Why?
|
| Lymphoma | 17 | 2023 | 1514 | 1.670 |
Why?
|
| Transplantation, Homologous | 35 | 2024 | 3036 | 1.270 |
Why?
|
| Vidarabine | 22 | 2024 | 1383 | 1.240 |
Why?
|
| Cyclophosphamide | 27 | 2024 | 3231 | 1.190 |
Why?
|
| Lymphoma, Non-Hodgkin | 10 | 2023 | 1068 | 1.190 |
Why?
|
| Adult | 157 | 2024 | 81933 | 1.170 |
Why?
|
| Depsipeptides | 5 | 2023 | 77 | 1.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 12 | 2018 | 609 | 1.160 |
Why?
|
| Hematologic Neoplasms | 19 | 2023 | 1950 | 1.140 |
Why?
|
| Breast Neoplasms | 40 | 2018 | 16244 | 1.120 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 5 | 2019 | 343 | 1.090 |
Why?
|
| Humans | 274 | 2024 | 272091 | 1.080 |
Why?
|
| Neoplasm Recurrence, Local | 32 | 2023 | 10365 | 1.050 |
Why?
|
| Middle Aged | 156 | 2024 | 90460 | 1.040 |
Why?
|
| Antineoplastic Agents | 30 | 2022 | 14653 | 1.020 |
Why?
|
| Salvage Therapy | 16 | 2021 | 2119 | 1.010 |
Why?
|
| Myeloablative Agonists | 10 | 2023 | 386 | 0.990 |
Why?
|
| Testicular Neoplasms | 5 | 2019 | 555 | 0.950 |
Why?
|
| Aged | 119 | 2024 | 73517 | 0.920 |
Why?
|
| Lymphoma, B-Cell | 4 | 2023 | 936 | 0.820 |
Why?
|
| Leukemia, Myeloid, Acute | 20 | 2024 | 7258 | 0.810 |
Why?
|
| Female | 161 | 2024 | 149288 | 0.810 |
Why?
|
| Disease-Free Survival | 44 | 2023 | 10259 | 0.790 |
Why?
|
| Cord Blood Stem Cell Transplantation | 10 | 2017 | 372 | 0.780 |
Why?
|
| Survival Analysis | 37 | 2022 | 9326 | 0.780 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2021 | 5421 | 0.770 |
Why?
|
| Male | 135 | 2024 | 129089 | 0.760 |
Why?
|
| Carmustine | 12 | 2019 | 224 | 0.760 |
Why?
|
| Young Adult | 57 | 2023 | 22142 | 0.730 |
Why?
|
| Hydroxamic Acids | 7 | 2016 | 455 | 0.730 |
Why?
|
| Lymphoma, T-Cell | 4 | 2016 | 369 | 0.720 |
Why?
|
| Treatment Outcome | 67 | 2024 | 33909 | 0.720 |
Why?
|
| Bone Marrow Transplantation | 8 | 2024 | 1772 | 0.710 |
Why?
|
| Recurrence | 26 | 2023 | 4887 | 0.700 |
Why?
|
| Retrospective Studies | 69 | 2024 | 39831 | 0.690 |
Why?
|
| Tacrolimus | 7 | 2022 | 351 | 0.690 |
Why?
|
| Fetal Blood | 9 | 2023 | 502 | 0.660 |
Why?
|
| Adolescent | 49 | 2024 | 32730 | 0.650 |
Why?
|
| Immunosuppressive Agents | 10 | 2017 | 1443 | 0.650 |
Why?
|
| Combined Modality Therapy | 34 | 2021 | 9046 | 0.620 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 418 | 0.610 |
Why?
|
| Mediastinal Neoplasms | 3 | 2015 | 429 | 0.570 |
Why?
|
| Prognosis | 38 | 2023 | 22555 | 0.560 |
Why?
|
| Antigens, CD19 | 7 | 2024 | 584 | 0.560 |
Why?
|
| Immunoconjugates | 5 | 2023 | 314 | 0.550 |
Why?
|
| Killer Cells, Natural | 5 | 2024 | 967 | 0.530 |
Why?
|
| Rituximab | 7 | 2023 | 1588 | 0.530 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 5 | 2018 | 218 | 0.510 |
Why?
|
| Survival Rate | 30 | 2021 | 12534 | 0.500 |
Why?
|
| DNA Damage | 8 | 2022 | 1989 | 0.490 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2018 | 5107 | 0.490 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2014 | 45 | 0.490 |
Why?
|
| Chromosome Aberrations | 9 | 2024 | 2035 | 0.480 |
Why?
|
| Epigenesis, Genetic | 3 | 2016 | 1439 | 0.460 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 3 | 2023 | 191 | 0.450 |
Why?
|
| Prospective Studies | 26 | 2024 | 13410 | 0.450 |
Why?
|
| Neoplasms, Second Primary | 6 | 2023 | 1388 | 0.430 |
Why?
|
| DNA Repair | 4 | 2022 | 1912 | 0.420 |
Why?
|
| Histone Deacetylase Inhibitors | 4 | 2024 | 621 | 0.420 |
Why?
|
| Mucormycosis | 1 | 2014 | 118 | 0.420 |
Why?
|
| Hematopoietic Stem Cells | 7 | 2015 | 1373 | 0.420 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2015 | 299 | 0.420 |
Why?
|
| Drug Synergism | 10 | 2024 | 1364 | 0.410 |
Why?
|
| Cisplatin | 10 | 2015 | 2497 | 0.400 |
Why?
|
| Kidney Diseases | 2 | 2015 | 732 | 0.400 |
Why?
|
| DNA | 4 | 2022 | 3089 | 0.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2020 | 2903 | 0.390 |
Why?
|
| Mycophenolic Acid | 4 | 2022 | 154 | 0.380 |
Why?
|
| Follow-Up Studies | 20 | 2021 | 15279 | 0.380 |
Why?
|
| Etoposide | 7 | 2018 | 905 | 0.370 |
Why?
|
| Autografts | 7 | 2023 | 179 | 0.370 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2024 | 135 | 0.370 |
Why?
|
| Antigens, CD34 | 7 | 2024 | 643 | 0.360 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2021 | 550 | 0.350 |
Why?
|
| Neoplasms | 14 | 2024 | 15930 | 0.350 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 1559 | 0.350 |
Why?
|
| Receptor, ErbB-2 | 6 | 2009 | 2649 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2013 | 2681 | 0.340 |
Why?
|
| Leukemia, Plasma Cell | 2 | 2020 | 43 | 0.340 |
Why?
|
| Remission Induction | 14 | 2024 | 3645 | 0.330 |
Why?
|
| Allografts | 10 | 2024 | 684 | 0.330 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2023 | 2319 | 0.330 |
Why?
|
| Neoplasm Staging | 15 | 2024 | 13993 | 0.320 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 1841 | 0.320 |
Why?
|
| Translocation, Genetic | 5 | 2023 | 1288 | 0.320 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2014 | 1351 | 0.320 |
Why?
|
| Age Factors | 8 | 2018 | 5526 | 0.320 |
Why?
|
| Living Donors | 2 | 2006 | 178 | 0.310 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 3363 | 0.300 |
Why?
|
| Drug Administration Schedule | 8 | 2017 | 3543 | 0.300 |
Why?
|
| Child | 23 | 2023 | 30559 | 0.300 |
Why?
|
| Azacitidine | 3 | 2024 | 1219 | 0.290 |
Why?
|
| Carboplatin | 7 | 2018 | 879 | 0.280 |
Why?
|
| T-Lymphocytes | 6 | 2023 | 3947 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 5 | 2008 | 4496 | 0.280 |
Why?
|
| Tissue Donors | 3 | 2022 | 812 | 0.280 |
Why?
|
| Dacarbazine | 2 | 2015 | 505 | 0.270 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2015 | 770 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 6 | 2018 | 271 | 0.260 |
Why?
|
| Hyperammonemia | 1 | 2006 | 67 | 0.260 |
Why?
|
| Multivariate Analysis | 9 | 2017 | 4352 | 0.260 |
Why?
|
| Bortezomib | 5 | 2022 | 542 | 0.260 |
Why?
|
| Lymphatic Metastasis | 5 | 2009 | 4968 | 0.260 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2018 | 2168 | 0.260 |
Why?
|
| DNA, Neoplasm | 2 | 2002 | 1972 | 0.260 |
Why?
|
| Benzoates | 2 | 2024 | 130 | 0.260 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2023 | 3148 | 0.250 |
Why?
|
| Ifosfamide | 6 | 2018 | 357 | 0.250 |
Why?
|
| Siblings | 3 | 2022 | 313 | 0.250 |
Why?
|
| Heterocyclic Compounds | 3 | 2015 | 119 | 0.250 |
Why?
|
| Drug Monitoring | 2 | 2017 | 356 | 0.240 |
Why?
|
| Hydrazines | 2 | 2024 | 214 | 0.240 |
Why?
|
| Doxorubicin | 7 | 2015 | 3132 | 0.240 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2016 | 50 | 0.240 |
Why?
|
| Unrelated Donors | 2 | 2016 | 321 | 0.230 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2019 | 285 | 0.230 |
Why?
|
| Lymphocyte Depletion | 2 | 2018 | 311 | 0.230 |
Why?
|
| Patient Selection | 5 | 2017 | 2045 | 0.230 |
Why?
|
| Neoplasm, Residual | 5 | 2023 | 1741 | 0.230 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2024 | 514 | 0.230 |
Why?
|
| ABO Blood-Group System | 2 | 2016 | 125 | 0.230 |
Why?
|
| Blood Component Removal | 1 | 2004 | 121 | 0.230 |
Why?
|
| Amifostine | 1 | 2004 | 99 | 0.230 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2006 | 235 | 0.230 |
Why?
|
| Toxoplasmosis | 1 | 2024 | 49 | 0.220 |
Why?
|
| Radiation-Protective Agents | 1 | 2004 | 129 | 0.220 |
Why?
|
| Thalidomide | 4 | 2017 | 595 | 0.220 |
Why?
|
| Bone Marrow | 5 | 2021 | 2446 | 0.220 |
Why?
|
| Sulfonamides | 5 | 2024 | 1919 | 0.210 |
Why?
|
| Ki-1 Antigen | 3 | 2023 | 186 | 0.210 |
Why?
|
| West Nile Fever | 1 | 2004 | 155 | 0.210 |
Why?
|
| Brain Neoplasms | 3 | 2018 | 4994 | 0.200 |
Why?
|
| Acetamides | 1 | 2023 | 113 | 0.200 |
Why?
|
| Histocompatibility Testing | 4 | 2018 | 484 | 0.200 |
Why?
|
| Administration, Intravenous | 1 | 2023 | 251 | 0.200 |
Why?
|
| Adenine Nucleotides | 4 | 2016 | 365 | 0.200 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2004 | 640 | 0.200 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 25 | 0.190 |
Why?
|
| Stomatitis | 1 | 2022 | 193 | 0.190 |
Why?
|
| Hepatic Encephalopathy | 2 | 1999 | 89 | 0.190 |
Why?
|
| Vascular Diseases | 1 | 2024 | 243 | 0.190 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2021 | 3395 | 0.190 |
Why?
|
| Time Factors | 14 | 2020 | 13139 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Pain, Intractable | 1 | 2022 | 179 | 0.190 |
Why?
|
| Arabinonucleosides | 4 | 2016 | 458 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1592 | 0.180 |
Why?
|
| Hepatitis C | 2 | 2016 | 551 | 0.180 |
Why?
|
| Dexamethasone | 6 | 2023 | 1497 | 0.180 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 485 | 0.180 |
Why?
|
| Platinum Compounds | 1 | 2001 | 129 | 0.180 |
Why?
|
| Pentostatin | 2 | 2017 | 121 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2005 | 1054 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 1599 | 0.180 |
Why?
|
| Cystitis | 1 | 2021 | 109 | 0.180 |
Why?
|
| Prednisone | 3 | 2018 | 1036 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2024 | 6885 | 0.170 |
Why?
|
| Cladribine | 2 | 2024 | 253 | 0.170 |
Why?
|
| Apoptosis | 8 | 2024 | 7837 | 0.170 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 31066 | 0.170 |
Why?
|
| Oophoritis | 1 | 1999 | 3 | 0.170 |
Why?
|
| Risk Factors | 14 | 2024 | 18051 | 0.170 |
Why?
|
| Taxoids | 4 | 2009 | 1010 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2021 | 1091 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2005 | 686 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2007 | 895 | 0.170 |
Why?
|
| Treatment Failure | 4 | 2017 | 1433 | 0.170 |
Why?
|
| Plasma | 1 | 2020 | 147 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2004 | 1280 | 0.170 |
Why?
|
| Biological Products | 1 | 2023 | 319 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2015 | 879 | 0.160 |
Why?
|
| Cause of Death | 3 | 2017 | 787 | 0.160 |
Why?
|
| Cell Line, Tumor | 13 | 2024 | 14881 | 0.160 |
Why?
|
| Histocompatibility | 2 | 2018 | 182 | 0.160 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 23 | 0.160 |
Why?
|
| Fatal Outcome | 5 | 2016 | 835 | 0.160 |
Why?
|
| ErbB Receptors | 1 | 2007 | 2383 | 0.160 |
Why?
|
| Reactive Oxygen Species | 3 | 2022 | 1011 | 0.160 |
Why?
|
| Liver Failure | 1 | 2019 | 142 | 0.160 |
Why?
|
| Vincristine | 3 | 2018 | 1572 | 0.160 |
Why?
|
| Paclitaxel | 4 | 2008 | 2099 | 0.160 |
Why?
|
| Bone Marrow Purging | 2 | 2011 | 88 | 0.160 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 195 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2020 | 2474 | 0.150 |
Why?
|
| Infusions, Intravenous | 4 | 2012 | 1442 | 0.150 |
Why?
|
| Incidence | 9 | 2024 | 5864 | 0.150 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 872 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2019 | 288 | 0.150 |
Why?
|
| Hepatitis B virus | 1 | 2019 | 225 | 0.150 |
Why?
|
| Neutrophils | 4 | 2015 | 876 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 89 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2024 | 1544 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2019 | 413 | 0.150 |
Why?
|
| Pancreatitis | 1 | 2000 | 293 | 0.150 |
Why?
|
| Cytarabine | 3 | 2019 | 2014 | 0.150 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 4890 | 0.150 |
Why?
|
| Liver Failure, Acute | 1 | 1998 | 98 | 0.140 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 276 | 0.140 |
Why?
|
| Mortality | 2 | 2018 | 355 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2005 | 499 | 0.140 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2016 | 30 | 0.140 |
Why?
|
| Thiotepa | 4 | 2024 | 132 | 0.140 |
Why?
|
| Neoplasm Metastasis | 6 | 2015 | 5330 | 0.140 |
Why?
|
| Radiography | 2 | 2014 | 1994 | 0.140 |
Why?
|
| Clinical Trials as Topic | 6 | 2005 | 3856 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2019 | 6270 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2020 | 731 | 0.140 |
Why?
|
| Acute Disease | 5 | 2022 | 2517 | 0.140 |
Why?
|
| Adenine | 1 | 2019 | 669 | 0.140 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 5118 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2016 | 1265 | 0.140 |
Why?
|
| Whole-Body Irradiation | 4 | 2016 | 324 | 0.130 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2016 | 50 | 0.130 |
Why?
|
| Receptors, KIR | 1 | 2016 | 64 | 0.130 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 122 | 0.130 |
Why?
|
| Hypothyroidism | 1 | 2018 | 211 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1020 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 617 | 0.130 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 10750 | 0.130 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2015 | 45 | 0.130 |
Why?
|
| Plasmablastic Lymphoma | 1 | 2015 | 37 | 0.130 |
Why?
|
| Genes, p53 | 1 | 2000 | 1146 | 0.130 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 996 | 0.130 |
Why?
|
| Cell Proliferation | 4 | 2017 | 7302 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2016 | 119 | 0.130 |
Why?
|
| Cell Survival | 3 | 2017 | 3074 | 0.130 |
Why?
|
| Cell Separation | 4 | 2017 | 616 | 0.130 |
Why?
|
| Splenic Neoplasms | 1 | 2016 | 125 | 0.130 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 671 | 0.130 |
Why?
|
| Drug Therapy, Combination | 6 | 2022 | 2369 | 0.130 |
Why?
|
| Cohort Studies | 8 | 2021 | 9500 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 1999 | 487 | 0.120 |
Why?
|
| Bevacizumab | 3 | 2015 | 957 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 58 | 0.120 |
Why?
|
| DNA Transposable Elements | 1 | 2016 | 252 | 0.120 |
Why?
|
| Central Nervous System | 3 | 2022 | 457 | 0.120 |
Why?
|
| Immunohistochemistry | 5 | 2016 | 7828 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 745 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 326 | 0.120 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 318 | 0.120 |
Why?
|
| Cardiomyopathies | 1 | 2000 | 560 | 0.120 |
Why?
|
| Hyphae | 1 | 2014 | 44 | 0.120 |
Why?
|
| Outpatients | 1 | 2017 | 469 | 0.120 |
Why?
|
| Carcinoma | 1 | 2006 | 2623 | 0.120 |
Why?
|
| Mucositis | 2 | 2012 | 150 | 0.120 |
Why?
|
| Piperidines | 1 | 2019 | 1091 | 0.120 |
Why?
|
| Graft Survival | 6 | 2017 | 1092 | 0.120 |
Why?
|
| Evidence-Based Medicine | 3 | 2009 | 1060 | 0.110 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 36 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 881 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2015 | 185 | 0.110 |
Why?
|
| Indoles | 2 | 2016 | 1034 | 0.110 |
Why?
|
| Signal Transduction | 5 | 2020 | 12223 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2018 | 473 | 0.110 |
Why?
|
| Blood Platelets | 2 | 2015 | 684 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2016 | 588 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 1590 | 0.110 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 313 | 0.110 |
Why?
|
| Maintenance Chemotherapy | 3 | 2019 | 224 | 0.110 |
Why?
|
| Propensity Score | 3 | 2021 | 776 | 0.100 |
Why?
|
| Cytogenetic Analysis | 3 | 2020 | 574 | 0.100 |
Why?
|
| Trastuzumab | 2 | 2006 | 736 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2003 | 2634 | 0.100 |
Why?
|
| Leukemia | 1 | 2021 | 1721 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 303 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2024 | 637 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 697 | 0.100 |
Why?
|
| Leukocyte Transfusion | 1 | 2012 | 44 | 0.100 |
Why?
|
| Transcriptome | 1 | 2021 | 1950 | 0.100 |
Why?
|
| Germinoma | 2 | 2004 | 84 | 0.100 |
Why?
|
| Gene Expression | 1 | 2000 | 3690 | 0.100 |
Why?
|
| Life Tables | 3 | 2000 | 122 | 0.100 |
Why?
|
| Primary Myelofibrosis | 1 | 2020 | 915 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2015 | 724 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1998 | 1237 | 0.100 |
Why?
|
| Retreatment | 3 | 2018 | 448 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 656 | 0.100 |
Why?
|
| Transplantation, Haploidentical | 2 | 2022 | 159 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 653 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 208 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2016 | 423 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 4400 | 0.090 |
Why?
|
| Fluorouracil | 3 | 2009 | 1988 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 2 | 2009 | 281 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 1998 | 791 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2014 | 690 | 0.090 |
Why?
|
| Plasma Cells | 2 | 2023 | 201 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 718 | 0.090 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 4811 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2022 | 4984 | 0.090 |
Why?
|
| Methylene Blue | 2 | 2022 | 53 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1335 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2011 | 355 | 0.080 |
Why?
|
| Registries | 1 | 2017 | 2253 | 0.080 |
Why?
|
| Positron-Emission Tomography | 4 | 2022 | 2198 | 0.080 |
Why?
|
| Alleles | 1 | 2015 | 2599 | 0.080 |
Why?
|
| Review Literature as Topic | 1 | 2009 | 83 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 3176 | 0.080 |
Why?
|
| Cell Count | 2 | 2013 | 524 | 0.080 |
Why?
|
| Benzylamines | 3 | 2015 | 101 | 0.080 |
Why?
|
| Risk | 2 | 2005 | 1950 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1860 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 131 | 0.080 |
Why?
|
| Pyrazines | 1 | 2011 | 513 | 0.080 |
Why?
|
| Stem Cells | 1 | 2015 | 1236 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 740 | 0.080 |
Why?
|
| Oxides | 1 | 2008 | 212 | 0.080 |
Why?
|
| Genotype | 1 | 2016 | 4267 | 0.080 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2020 | 128 | 0.080 |
Why?
|
| Arsenicals | 1 | 2008 | 204 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2015 | 1472 | 0.070 |
Why?
|
| Nucleosides | 2 | 2022 | 63 | 0.070 |
Why?
|
| Child, Preschool | 8 | 2017 | 17056 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2000 | 729 | 0.070 |
Why?
|
| Phthalazines | 2 | 2022 | 263 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2010 | 382 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2022 | 2621 | 0.070 |
Why?
|
| Steroids | 2 | 2020 | 375 | 0.070 |
Why?
|
| United States | 6 | 2023 | 16066 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2021 | 3546 | 0.070 |
Why?
|
| Lymphatic Irradiation | 1 | 2007 | 139 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 4071 | 0.070 |
Why?
|
| Leucovorin | 2 | 1998 | 344 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2010 | 274 | 0.070 |
Why?
|
| Forecasting | 2 | 2000 | 706 | 0.070 |
Why?
|
| Cytotoxins | 2 | 2020 | 65 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 5248 | 0.070 |
Why?
|
| Feasibility Studies | 4 | 2016 | 2355 | 0.070 |
Why?
|
| Drug Interactions | 2 | 2018 | 585 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1327 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2009 | 3080 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 1 | 2006 | 148 | 0.070 |
Why?
|
| Proteasome Inhibitors | 2 | 2017 | 234 | 0.060 |
Why?
|
| Leukapheresis | 3 | 2009 | 166 | 0.060 |
Why?
|
| Antioxidants | 1 | 2008 | 523 | 0.060 |
Why?
|
| Pregnancy Trimester, First | 1 | 2006 | 126 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2006 | 240 | 0.060 |
Why?
|
| Databases, Factual | 3 | 2016 | 2290 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2005 | 296 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 7958 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 4964 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2017 | 5804 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2020 | 569 | 0.060 |
Why?
|
| Meningoencephalitis | 1 | 2004 | 28 | 0.060 |
Why?
|
| Fetal Development | 1 | 2006 | 118 | 0.060 |
Why?
|
| Comorbidity | 2 | 2023 | 2439 | 0.060 |
Why?
|
| Advisory Committees | 1 | 2005 | 209 | 0.060 |
Why?
|
| Pharmacokinetics | 1 | 2004 | 40 | 0.060 |
Why?
|
| Cell Culture Techniques | 5 | 2012 | 584 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2007 | 1323 | 0.060 |
Why?
|
| Lung | 1 | 2015 | 3295 | 0.060 |
Why?
|
| Methylprednisolone | 2 | 2016 | 200 | 0.060 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2016 | 294 | 0.060 |
Why?
|
| Infant | 5 | 2015 | 13970 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 1260 | 0.050 |
Why?
|
| Placebos | 1 | 2004 | 446 | 0.050 |
Why?
|
| Poly ADP Ribosylation | 1 | 2022 | 9 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2015 | 2337 | 0.050 |
Why?
|
| Anemia, Sideroblastic | 1 | 2003 | 58 | 0.050 |
Why?
|
| Amino Acids | 1 | 2006 | 788 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2005 | 1436 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2024 | 189 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 1720 | 0.050 |
Why?
|
| Anthracenes | 1 | 2022 | 47 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2006 | 681 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 214 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 1136 | 0.050 |
Why?
|
| Sex Factors | 2 | 2017 | 2208 | 0.050 |
Why?
|
| Alkylating Agents | 1 | 2022 | 82 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2022 | 163 | 0.050 |
Why?
|
| Donor Selection | 1 | 2022 | 106 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2022 | 406 | 0.050 |
Why?
|
| Neutropenia | 3 | 2017 | 1001 | 0.050 |
Why?
|
| British Columbia | 1 | 2021 | 26 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2006 | 865 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 3544 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2018 | 3078 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2005 | 906 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 2270 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Methotrexate | 2 | 2022 | 1033 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 155 | 0.050 |
Why?
|
| STAT5 Transcription Factor | 1 | 2022 | 227 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2021 | 116 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2022 | 481 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 613 | 0.050 |
Why?
|
| Piperazines | 2 | 2022 | 2152 | 0.050 |
Why?
|
| Ovarian Neoplasms | 3 | 2004 | 4797 | 0.050 |
Why?
|
| Blood | 1 | 2021 | 172 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 3671 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2003 | 485 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2022 | 289 | 0.040 |
Why?
|
| X-Ray Therapy | 1 | 2000 | 6 | 0.040 |
Why?
|
| Germinal Center | 1 | 2021 | 168 | 0.040 |
Why?
|
| Melanoma | 2 | 2008 | 5592 | 0.040 |
Why?
|
| Philadelphia | 1 | 2000 | 36 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 5001 | 0.040 |
Why?
|
| Animals | 5 | 2024 | 62827 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 848 | 0.040 |
Why?
|
| Caspases | 1 | 2022 | 687 | 0.040 |
Why?
|
| France | 1 | 2000 | 121 | 0.040 |
Why?
|
| Cytokines | 2 | 2021 | 2841 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2022 | 451 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2004 | 809 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 2020 | 208 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 65 | 0.040 |
Why?
|
| Analgesics | 1 | 2022 | 410 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2001 | 1086 | 0.040 |
Why?
|
| Mothers | 1 | 2022 | 418 | 0.040 |
Why?
|
| Retroviridae | 1 | 2020 | 376 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 1659 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 216 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2018 | 51 | 0.040 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2022 | 409 | 0.040 |
Why?
|
| Anuria | 1 | 1998 | 15 | 0.040 |
Why?
|
| Bone Marrow Diseases | 1 | 2000 | 187 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 324 | 0.040 |
Why?
|
| Multiple Organ Failure | 1 | 2000 | 177 | 0.040 |
Why?
|
| Mastectomy | 1 | 2005 | 1557 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 154 | 0.040 |
Why?
|
| Jaundice | 1 | 1998 | 39 | 0.040 |
Why?
|
| Drug Design | 1 | 2001 | 378 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 1999 | 233 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 566 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 691 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 371 | 0.040 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1998 | 72 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 139 | 0.040 |
Why?
|
| Probability | 1 | 1999 | 887 | 0.040 |
Why?
|
| Antidotes | 1 | 1997 | 27 | 0.040 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 2029 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1547 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2022 | 1055 | 0.040 |
Why?
|
| Antilymphocyte Serum | 2 | 2012 | 237 | 0.040 |
Why?
|
| Disease Progression | 3 | 2018 | 6911 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2024 | 1483 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2000 | 578 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 32 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 382 | 0.040 |
Why?
|
| Texas | 3 | 2013 | 6440 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 1050 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2017 | 274 | 0.040 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 212 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 1999 | 242 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2022 | 1855 | 0.030 |
Why?
|
| Histones | 2 | 2016 | 1514 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2018 | 615 | 0.030 |
Why?
|
| Therapeutics | 1 | 2016 | 31 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2016 | 86 | 0.030 |
Why?
|
| Binding Sites | 1 | 2001 | 2298 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2004 | 784 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 2268 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 2016 | 72 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2002 | 1327 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2015 | 1589 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 2016 | 116 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 151 | 0.030 |
Why?
|
| Isochromosomes | 1 | 2016 | 55 | 0.030 |
Why?
|
| Haplotypes | 2 | 2012 | 909 | 0.030 |
Why?
|
| Photopheresis | 1 | 2016 | 79 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 124 | 0.030 |
Why?
|
| Inflammation | 1 | 2006 | 2535 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2000 | 506 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 163 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2016 | 122 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 267 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2021 | 5788 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2002 | 1190 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 186 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2016 | 172 | 0.030 |
Why?
|
| Histone Code | 1 | 2016 | 86 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 79 | 0.030 |
Why?
|
| Splenomegaly | 1 | 2016 | 173 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 1116 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 289 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2016 | 233 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1113 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 372 | 0.030 |
Why?
|
| Trisomy | 1 | 2016 | 240 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 78 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 109 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 330 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 110 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 436 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 2058 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2267 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 168 | 0.030 |
Why?
|
| Phenotype | 2 | 2016 | 6517 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 327 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2020 | 1887 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 342 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 126 | 0.030 |
Why?
|
| Vinblastine | 1 | 2015 | 462 | 0.030 |
Why?
|
| Plasmids | 1 | 2016 | 953 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1998 | 1622 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1827 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 689 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 313 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 540 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 482 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 174 | 0.030 |
Why?
|
| Brain | 1 | 2007 | 4260 | 0.030 |
Why?
|
| Bleomycin | 1 | 2015 | 482 | 0.030 |
Why?
|
| Mediastinum | 1 | 2015 | 278 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 5756 | 0.030 |
Why?
|
| Recombinant Proteins | 3 | 2009 | 3072 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2000 | 931 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2012 | 38 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 460 | 0.030 |
Why?
|
| Transplantation Immunology | 1 | 2013 | 107 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2016 | 366 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 408 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1996 | 417 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 669 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2012 | 173 | 0.030 |
Why?
|
| Pregnancy | 1 | 2006 | 8105 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2012 | 234 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 375 | 0.030 |
Why?
|
| Lymphocyte Transfusion | 1 | 2013 | 174 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 605 | 0.030 |
Why?
|
| Research Design | 1 | 2000 | 1581 | 0.030 |
Why?
|
| Radiometry | 1 | 2018 | 1017 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 7792 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1732 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2012 | 131 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1212 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 1728 | 0.020 |
Why?
|
| Blood Donors | 1 | 2012 | 173 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 99 | 0.020 |
Why?
|
| DNA Primers | 1 | 2013 | 1513 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 655 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 322 | 0.020 |
Why?
|
| Acetylation | 1 | 2011 | 517 | 0.020 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 272 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2016 | 755 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2457 | 0.020 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2010 | 39 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 437 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 5067 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 2002 | 738 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 320 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 3646 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2010 | 6236 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1338 | 0.020 |
Why?
|
| Epirubicin | 1 | 2009 | 159 | 0.020 |
Why?
|
| Filgrastim | 1 | 2009 | 194 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 1575 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 4900 | 0.020 |
Why?
|
| Mitochondria | 1 | 2016 | 1314 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5187 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2009 | 85 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 2085 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1739 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2012 | 622 | 0.020 |
Why?
|
| Capecitabine | 1 | 2009 | 390 | 0.020 |
Why?
|
| Virus Activation | 1 | 2010 | 236 | 0.020 |
Why?
|
| PubMed | 1 | 2008 | 33 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 3427 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1469 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 2504 | 0.020 |
Why?
|
| Publishing | 1 | 2009 | 196 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 3469 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 908 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 4003 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 3651 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 752 | 0.020 |
Why?
|
| Palliative Care | 1 | 1998 | 2161 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 6489 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 5502 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 2761 | 0.020 |
Why?
|
| Fever | 1 | 2009 | 516 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1998 | 2669 | 0.020 |
Why?
|
| Publications | 1 | 2005 | 54 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2016 | 4195 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 2452 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 1905 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3153 | 0.010 |
Why?
|
| Biomarkers | 1 | 2015 | 5115 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2012 | 2129 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2004 | 296 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 624 | 0.010 |
Why?
|
| Mice | 1 | 2024 | 36056 | 0.010 |
Why?
|
| Behavior Therapy | 1 | 2004 | 304 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2004 | 606 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 2000 | 88 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 9101 | 0.010 |
Why?
|
| Thrombopoietin | 1 | 2000 | 102 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 15944 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1998 | 7976 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2005 | 1349 | 0.010 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1998 | 75 | 0.010 |
Why?
|
| Tegafur | 1 | 1997 | 51 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 1997 | 227 | 0.010 |
Why?
|
| Uracil | 1 | 1997 | 67 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2000 | 642 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 2711 | 0.010 |
Why?
|
| Growth Substances | 1 | 1997 | 329 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1997 | 171 | 0.010 |
Why?
|
| Triglycerides | 1 | 1998 | 622 | 0.010 |
Why?
|
| Diarrhea | 1 | 1997 | 730 | 0.010 |
Why?
|
| Anemia | 1 | 1997 | 730 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1998 | 3980 | 0.010 |
Why?
|